CYCLOSET® (BROMOCRIPTINE)
















  • Baseline A1C ∼8.9%
  • In the Cycloset® group, 69% of patients achieved the maximum does (4.8 mg a day)
  • Difference between groups (0.4%) was statistically significant
  • Reference [1]
Cycloset® monotherapy
24 week, placebo-controlled trial
Cycloset® 1.6 - 4.8 mg a day
(N=80)
Placebo
(N=79)
HgA1C
(average change at 24 weeks)
-0.10%
+0.3%

  • Baseline A1C ∼8.3%
  • Difference between groups (0.5%) was statistically significant
  • Reference [1]
Cycloset® added to metformin and sulfonylurea
24 week, placebo-controlled trial
Cycloset® 1.6 - 4.8 mg a day
(N=177)
Placebo
(N=90)
HgA1C
average change at 24 weeks
-0.50%
0.0%



Reference [1]
Monotherapy, placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
N=80
Placebo
N=79
Nausea 33% 8%
Constipation 11% 4%
Diarrhea 9% 5%
Upset stomach 8% 3%
Vomiting 6% 1%
Decreased appetite 5% 1%


Reference [1]
Monotherapy, placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
N=80
Placebo
N=79
Runny nose (Rhinitis) 14% 4%
Sinusitis 10% 3%


Reference [1]
Monotherapy, placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
N=80
Placebo
N=79
Weakness 13% 6%
Dizziness 13% 8%


Reference [1]
Monotherapy, placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
N=80
Placebo
N=79
Vision changes 8% 1%


Reference [1]
Monotherapy, placebo-controlled trials
Side effect Cycloset 1.6 - 4.8 mg daily
N=80
Placebo
N=79
Headache 13% 9%